17 research outputs found
PREDICTORS OF TWO–YEAR MORTALITY AND RISK STRATIFICATION FOR PATIENTS WITH CRITICAL LIMB ISCHEMIA TREATED WITH ENDOVASCULAR OR SURGICAL BYPASS RECONSTRUCTION
No full textLong-Term Results of Endovascular Therapy With Nitinol Stent Implantation for TASC II A/B Femoro-Popliteal Artery Lesions
No full textDrug-Coated Balloon Angioplasty in Atherosclerosis Patients With Popliteal Artery Involvement
No full textP2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
No full textAbstract It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing complex percutaneous coronary intervention (PCI). We performed a systematic review and meta-analysis to evaluate P2Y12 inhibitor monotherapy vs. conventional DAPT in patients undergoing complex PCI and non-complex PCI (PROSPERO: CRD42022335723). Primary endpoint was the 1-year Net Adverse Clinical Event (NACE). Among 5,323 screened studies, six randomized trials fulfilled the eligibility criteria. A total of 10,588 complex PCI patients (5,269 vs. 5,319 patients) and 25,618 non-complex PCI patients (12,820 vs 12,798 patients) were randomly assigned to P2Y12 inhibitor monotherapy vs. conventional DAPT. In complex PCI patients, P2Y12 inhibitor monotherapy was associated with a lower risk of NACE than conventional DAPT [Odds ratio (OR) 0.76, 95% confidence interval (CI) 0.63–0.91, P = 0.003], whereas in non-complex PCI patients, P2Y12 inhibitor monotherapy was associated with a trend toward lowering the risk of NACE (OR 0.86, 95% CI 0.72–1.02, P = 0.09). This meta-analysis across randomized trials demonstrated that a strategy of short DAPT followed by P2Y12 inhibitor monotherapy reduces the risk of 1-year NACE in patients undergoing complex PCI
CLINICAL OUTCOMES AND RISK STRATIFICATION AFTER ENDOVASCULAR THERAPY FOR CRITICAL LIMB ISCHEMIA IN PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS
No full text18-0177_Supplementary_Materials – Supplemental material for Drug-Coated Balloon Angioplasty in Atherosclerosis Patients With Popliteal Artery Involvement
No full text<p>Supplemental material, 18-0177_Supplementary_Materials for Drug-Coated Balloon Angioplasty in Atherosclerosis Patients With Popliteal Artery Involvement by Tomoharu Dohi, Andrej Schmidt, Dierk Scheinert, Yvonne Bausback, Daijiro Kabata, Ayumi Shintani, Yasushi Sakata and Sabine Steiner in Journal of Endovascular Therapy</p
ANGIOSCOPIC ASSESSMENT OF PERI-STENT CONTRAST STAINING FOLLOWING DRUG-ELUTING STENT IMPLANTATION
No full textMIDTERM OUTCOMES AND RISK STRATIFICATION OF PLAIN BALLOON ANGIOPLASTY FOR IN STENT RESTENOSIS AFTER FEMOROPOPLITEAL STENTING
No full text
Study protocol for the PURSUIT-HFpEF study: A Prospective, Multicenter, Observational Study of Patients with Heart Failure with Preserved Ejection Fraction
Get PDFSuna S, Hikoso S, Yamada T On behalf of the OCVC-Heart Failure Investigators, et al. Study protocol for the PURSUIT-HFpEF study: a Prospective, Multicenter, Observational Study of Patients with Heart Failure with Preserved Ejection Fraction. BMJ Open 2020;10:e038294. doi: 10.1136/bmjopen-2020-03829
